全球多发性硬化症治疗药物市场规模、份额、成长分析、按药物类型、给药途径- 2023-2030 年产业预测

Global Multiple Sclerosis Drugs Market Size, Share, Growth Analysis, By Drug Type(Immunomodulatory, Immunosuppressant), By Route of Administration(Oral and Parenteral) - Industry Forecast 2023-2030

出版日期: 2024年02月11日 | 出版商:

SkyQuest | 英文 157 Pages | 商品交期: 3-5个工作天内

价格

简介目录

2022年全球多发性硬化症药物市场规模为246.4亿美元，预测期间（2024-2031年）复合年增长率为3.10%，从2023年的254亿美元增至2031年的32.4亿美元。成长至3000万美元。

由于多发性硬化症（MS）增加等因素，该市场预计未来将快速成长。根据2020年12月出版的《多发性硬化症图谱第三版洞察》，全球约有280万人（每10万人中有35.9人）受到多发性硬化症的影响。全球多发性硬化症的患病率正在增加，但盛行率估计值仍有差距在所有 75 个报告国家中，总总合为每年每10 万人中2.1 例，平均诊断年龄为32 岁。女性被诊断患有MS 的可能性也是男性的两倍。

使用自上而下和自下而上的方法来估计和检验全球多发性硬化症药物市场的规模，并估计其他各个相关子市场的规模。用于估计市场规模的调查方法包括以下细节：透过二次研究确定市场的主要企业，并透过初步和二次研究确定每个地区的市场占有率。整个过程包括研究主要企业的年度报告和财务报告，以及广泛的采访，以获取首席执行官、副总裁、董事和营销负责人等行业领导者的关键见解。马苏。所有股份比率和细分均使用二手资讯确定并使用主要资讯检验。本研究涵盖的所有可能影响市场的参数都经过详细考虑，并透过初步研究检验并进行分析，以获得最终的定量和定性资料。

全球多发性硬化症药物细分市场分析

多发性硬化症药物的全球市场根据药物类型、给药途径和地区进行细分。依药物类型划分，市场分为免疫调节剂、免疫抑制剂、干扰素和皮质类固醇。依给药途径，市场分为口服药物和肠胃外药物。依地区划分，分为北美、欧洲、亚太地区、中东/非洲、拉丁美洲。

推动多发性硬化症药物全球市场的因素

目前用于治疗多发性硬化症的药物经常接受进一步的测试，以了解更多用途或扩大适应症。例如，某些最初批准用于復发缓解型多发性硬化症的药物后来被批准用于次发性进行性和临床孤立症候群。这一扩大的适应症扩大了可能受益于这些药物的患者范围，从而增加了销售并扩大了市场。

在许多国家，政府和保险公司对用于治疗多发性硬化症（MS）的药物製定了优惠的报销政策。这些政策旨在透过减轻患者的经济负担来改善患者获得药物的机会。提供报销支持将使更多患者能够负担昂贵的多发性硬化症药物，从而推动市场成长。

全球多发性硬化症药物市场的限制因素

多发性硬化症药物，尤其是新的疾病修正治疗，通常成本高。这些成本给患者、医疗保健系统和付款人带来了巨大的经济挑战。对昂贵的多发性硬化症药物的价格和可用性的限制可能会阻碍其普及并抑制市场扩张，特别是在医疗保健预算有限和保险覆盖范围不足的地区。

全球多发性硬化症治疗药物市场趋势

疾病修正治疗(DMT) 的进步对于多发性硬化症的治疗至关重要。这是因为DMT在降低復发率、减缓疾病进展和保护神经功能方面发挥作用。市面上不断出现具有更高功效和安全性的新型增强型 DMT，包括单株抗体和口服疗法。 DMT 增强仍然是市场驱动力，为患者提供广泛的疾病管理选择。

执行摘要
调查方法
母市场分析
主要市场考察
- 技术分析
- 价格分析
- 供应链分析
- 价值链分析
- 市场生态系统
- 智慧财产权分析
- 贸易分析
- Start-Ups分析
- 原料分析
- 创新矩阵
- 研发线产品分析
- 总体经济指标
- 主要投资分析
- 关键成功因素
- 竞争程度
市场动态及展望
- 市场动态
  - 促进因素
  - 机会
  - 抑制因素
  - 任务
- 监管形势
- 波特的分析
- 对未来中断的特殊考虑
多发性硬化症药物的全球市场：依药物类型
- 市场概况
- 免疫调节
- 免疫抑制剂
- 干扰素
- 皮质类固醇
多发性硬化症药物的全球市场：按给药途径
- 市场概况
- 口服和肠胃外
多发性硬化症药物的全球市场规模：按地区划分
- 市场概况
- 北美洲
  - 美国
  - 加拿大
- 欧洲
  - 德国
  - 西班牙
  - 法国
  - 英国
  - 其他欧洲国家地区
- 亚太地区
  - 中国
  - 印度
  - 日本
  - 韩国
  - 其他亚太地区
- 拉丁美洲
  - 巴西
  - 其他拉丁美洲地区
- 中东和非洲 (MEA)
  - 海湾合作委员会国家
  - 南非
  - 其他中东/非洲地区
竞争形势
- 前5名企业对比
- 主要企业市场定位（2021年）
- 主要市场参与者所采取的策略
- 关键成功策略
- 近期市集活动
- 主要企业市场占有率（2021年）
主要企业简介
- Biogen Inc.（United States）
- Roche Holdings AG（Switzerland）
- Novartis AG（Switzerland）
- Sanofi SA（France）
- Merck & Co., Inc.（United States）
- Teva Pharmaceutical Industries Ltd.（Israel）
- Bayer AG（Germany）
- Pfizer Inc.（United States）
- GlaxoSmithKline plc（United Kingdom）
- AbbVie Inc.（United States）
- Johnson & Johnson Services, Inc.（United States）
- Celgene Corporation（United States）
- Bristol-Myers Squibb Company（United States）
- Mitsubishi Tanabe Pharma Corporation（Japan）
- Biogen Idec International GmbH（Switzerland）
- Genzyme Corporation（United States）
- F. Hoffmann-La Roche Ltd（Switzerland）
- Merck KGaA（Germany）
- Mylan NV（United States）
- Eisai Co., Ltd.（Japan）
- Takeda Pharmaceutical Company Limited（Japan）
- Ipsen（France）

简介目录

Product Code: SQMIG35I2199

Global Multiple Sclerosis Drugs Market size was valued at USD 24.64 Billion in 2022 and is poised to grow from USD 25.40 Billion in 2023 to USD 32.43 Billion by 2031, at a CAGR of 3.10% during the forecast period (2024-2031).

Due to factors such as the rising occurrence of multiple sclerosis (MS), the market in focus is expected to witness rapid growth in the future. According to a study published in December 2020 titled "Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition," it is estimated that approximately 2.8 million individuals (equating to 35.9 per 100,000 people) worldwide are believed to be affected by MS. The prevalence of MS has shown a global increase, although there are still gaps in the estimates of prevalence. Across all 75 reporting nations, the combined incidence rate stands at 2.1 per 100,000 people annually, with an average age of diagnosis being 32. Additionally, females are twice as likely as males to be diagnosed with MS.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Multiple Sclerosis Drugs Market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analysed to get the final quantitative and qualitative data.

Global Multiple Sclerosis Drugs Market Segmental Analysis

Global Multiple Sclerosis Drugs Market is segmented on the basis of Drug Type, Route of Administration and region. By Drug Type, the market is segmented into Immunomodulatory, Immunosuppressant, Interferons, Corticosteroids. By Route of Administration, market is segmented into Oral and Parenteral. By region, the market is segmented into North America, Europe, Asia Pacific, Middle East and Africa, and Latin America.

Drivers of the Global Multiple Sclerosis Drugs Market

Drugs currently utilized in multiple sclerosis treatment are frequently subjected to further testing for additional uses and expanded indications. For instance, certain medications initially sanctioned for relapsing-remitting MS have subsequently obtained approvals for secondary progressive MS or clinically isolated syndrome. These expanded indications broaden the range of patients who can potentially benefit from these drugs, thereby resulting in heightened sales and market expansion.

In numerous countries, governments and insurance firms have instituted favourable reimbursement policies for drugs used in treating multiple sclerosis (MS). These policies are designed to enhance patient access to medications by alleviating financial burdens. By providing reimbursement support, more patients can afford costly MS drugs, thereby stimulating market growth.

Restraints in the Global Multiple Sclerosis Drugs Market

MS medications, particularly the newer disease-modifying therapies, are frequently linked with considerable expenses. These costs can impose significant financial challenges on patients, healthcare systems, and payers alike. The restricted affordability and access to expensive MS drugs may hinder their uptake and constrain market expansion, particularly in areas with constrained healthcare budgets or insufficient insurance coverage.

Market Trends of the Global Multiple Sclerosis Drugs Market

The advancement of disease-modifying therapies (DMTs) is pivotal in the management of MS, as they serve to decrease relapse rates, postpone disease advancement, and safeguard neurological function. The market has seen the emergence of novel and enhanced DMTs, including monoclonal antibodies and oral treatments, which offer improved efficacy and safety attributes. The emphasis on enhancing DMTs remains a driving force in the market, offering patients a broader array of choices for managing the disease.

Executive Summary
- Market Overview
- Wheel of Fortune
Research Methodology
- Information Procurement
- Secondary & Primary Data Sources
- Market Size Estimation
- Market Assumptions & Limitations
Parent Market Analysis
- Market Overview
- Market Size
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
Key Market Insights
- Technology Analysis
- Pricing Analysis
- Supply Chain Analysis
- Value Chain Analysis
- Ecosystem of the Market
- IP Analysis
- Trade Analysis
- Startup Analysis
- Raw Material Analysis
- Innovation Matrix
- Pipeline Product Analysis
- Macroeconomic Indicators
- Top Investment Analysis
- Key Success Factor
- Degree of Competition
Market Dynamics & Outlook
- Market Dynamics
  - Drivers
  - Opportunities
  - Restraints
  - Challenges
- Regulatory Landscape
- Porters Analysis
  - Competitive rivalry
  - Threat of Substitute Products
  - Bargaining Power of Buyers
  - Threat of New Entrants
  - Bargaining Power of Suppliers
- Skyquest Special Insights on Future Disruptions
  - Political Impact
  - Economic Impact
  - Social Impact
  - Technical Impact
  - Environmental Impact
  - Legal Impact
Global Multiple Sclerosis Drugs Market by Drug Type
- Market Overview
- Immunomodulatory
- Immunosuppressant
- Interferons
- Corticosteroids
Global Multiple Sclerosis Drugs Market by Route of Administration
- Market Overview
- Oral and Parenteral
Global Multiple Sclerosis Drugs Market Size by Region
- Market Overview
- North America
  - USA
  - Canada
- Europe
  - Germany
  - Spain
  - France
  - UK
  - Rest of Europe
- Asia Pacific
  - China
  - India
  - Japan
  - South Korea
  - Rest of Asia-Pacific
- Latin America
  - Brazil
  - Rest of Latin America
- Middle East & Africa (MEA)
  - GCC Countries
  - South Africa
  - Rest of MEA
Competitive Landscape
- Top 5 Player Comparison
- Market Positioning of Key Players, 2021
- Strategies Adopted by Key Market Players
- Top Winning Strategies
  - By Development
  - By Company
  - By Year
- Recent Activities in the Market
- Key Companies Market Share (%), 2021
Key Company Profiles
- Biogen Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Roche Holdings AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Novartis AG (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Sanofi S.A. (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck & Co., Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Teva Pharmaceutical Industries Ltd. (Israel)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bayer AG (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Pfizer Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- GlaxoSmithKline plc (United Kingdom)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- AbbVie Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Johnson & Johnson Services, Inc. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Celgene Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Bristol-Myers Squibb Company (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mitsubishi Tanabe Pharma Corporation (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Biogen Idec International GmbH (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Genzyme Corporation (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- F. Hoffmann-La Roche Ltd (Switzerland)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Merck KGaA (Germany)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Mylan N.V. (United States)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Eisai Co., Ltd. (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Takeda Pharmaceutical Company Limited (Japan)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments
- Ipsen (France)
  - Company Overview
  - Business Segment Overview
  - Financial Updates
  - Key Developments